Basic Information
Wyost
Regulatory Information
EMEA/H/C/006378
May 17, 2024
March 21, 2024
2
February 12, 2025
Company Information
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Prevention of skeletal related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone. Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Overview Summary
Wyost is a medicine used to prevent bone complications in adults with advanced cancer that has spread to the bone. These complications include fractures (breaks in the bone), spinal compression (pressure on the spinal cord caused by damage to the surrounding bone), or bone problems requiring radiotherapy (treatment with radiation) or surgery. Wyost is also used to treat a type of bone cancer called giant cell tumour of bone in adults and in adolescents whose bones have fully developed. It is used in patients who cannot be treated by surgery or in whom surgery is likely to cause serious complications. Wyost is a biological medicine and contains the active substance denosumab. It is a ‘biosimilar medicine’; this means that Wyost is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Wyost is Xgeva. For more information on biosimilar medicines, see [here](https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines).